4/11/2024

Sodium Acetate Injection

Products Affected - Description

- Sodium acetate injection, Pfizer, 2 mEq/mL, 100 mL vial, 25 count, NDC 00409-3299-06
- Sodium acetate injection, Pfizer, 2 mEq/mL, 20 mL vial, 25 count, NDC 00409-7299-73
- Sodium acetate injection, Pfizer, 2 mEq/mL, 50 mL vial, 25 count, NDC 00409-3299-05

Reason for the Shortage

- Fresenius Kabi has sodium acetate injection available
- Pfizer has sodium acetate injection on shortage due to manufacturing delays.
- Woodward Pharma has sodium acetate injection available.

Available Products

- Sodium acetate injection, Fresenius Kabi, 4 mEq/mL, 100 mL vial, 20 count, NDC 63323-0032-00
- Sodium acetate injection, Woodward, 2 mEq/mL, 100 mL vial, 10 count, NDC 69784-0231-10
- Sodium acetate injection, Woodward, 2 mEq/mL, 50 mL vial, 10 count, NDC 69784-0230-10
- Sodium acetate injection, Woodward, 4 mEq/mL, 100 mL vial, 10 count, NDC 69784-0232-01

Estimated Resupply Dates

- Pfizer has sodium acetate 2 mEq/mL 20 mL vials on back order and the company estimates a release date of June 2024. The 50 mL and 100 mL vials are only available for emergency orders via direct orders.

Updated

Updated April 11, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 1, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.